Study of Continuous Glucose Monitoring to Improve Diabetes Care in Adults Aged 18 to 75 in Underserved Communities

What this Trial Is About

Researchers are conducting a randomized clinical trial to study continuous glucose monitoring CGM in adults with type 2 diabetes who are either uninsured or on Medicaid and use at least one daily insulin injection. The goal is to address health disparities and improve care for this underserved population. This pilot study will test the feasibility of a larger multicenter trial. Participants will be randomly assigned to either use continuous glucose monitoring devices, which are placed under the skin every 14 days, or continue with self-monitoring of blood glucose after a two-week run-in period. Both groups will receive diabetes education. Those in the self-monitoring group can optionally use the CGM device for three months after the six-month follow-up period. During the study, participant glucose control will be measured by changes in HbA1c and time spent in target glucose range over six months. Researchers will also track episodes of low blood sugar. Participants will be followed for six months, with assessments at the start and end of this period, and optional CGM use thereafter. The study team will monitor health outcomes, patient-reported experiences, and healthcare usage throughout the trial.

Continuous Glucose Monitoring (CGM) in an Underserved Population